Structural Basis for the Inhibition of Cyclin G‐Associated Kinase by Gefitinib
Autor: | Miyuki Kato-Murayama, Tamami Uejima, Naomi Ohbayashi, Hiroshi Nojima, Mutsuko Kukimoto-Niino, Shigeyuki Yokoyoma, Noboru Ohsawa, Kazutaka Murayama, Mikako Shirouzu, Takayoshi Matsuda |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
gefitinib medicine.disease_cause Virus lcsh:Chemistry 03 medical and health sciences Gefitinib complex structures medicine Epidermal growth factor receptor Binding site neoplasms Cyclin Mutation protein kinases biology Full Paper Chemistry Kinase General Chemistry Full Papers novel binding sites inhibitor development Cell biology respiratory tract diseases 030104 developmental biology Protein kinase domain lcsh:QD1-999 biology.protein medicine.drug |
Zdroj: | ChemistryOpen, Vol 7, Iss 9, Pp 713-719 (2018) ChemistryOpen |
ISSN: | 2191-1363 |
Popis: | Gefitinib is the molecular target drug for advanced non‐small‐cell lung cancer. The primary target of gefitinib is the positive mutation of epidermal growth factor receptor, but it also inhibits cyclin G‐associated kinase (GAK). To reveal the molecular bases of GAK and gefitinib binding, structure analyses were conducted and determined two forms of the gefitinib‐bound nanobody⋅GAK kinase domain complex structures. The first form, GAK_1, has one gefitinib at the ATP binding pocket, whereas the second form, GAK_2, binds one each in the ATP binding site and a novel binding site adjacent to the activation segment C‐terminal helix, a unique element of the Numb‐associated kinase family. In the novel binding site, gefitinib binds in the hydrophobic groove around the activation segment, disrupting the conserved hydrogen bonds for the catalytic activity. These structures suggest possibilities for the development of selective GAK inhibitors for viral infections, such as the hepatitis C virus. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |